Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009

2008200720062004

2016 Archives

May 3, 2016
--Company Reports Record Net Sales of $164 Million, Adjusted Operating Income of $65 Million; Continues to Expect its Fourth Quarter to Be In Line with Previous Outlook--

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2016 third quarter and nine months ended March 31, 2016. As previously announced, the company completed the...

More
Apr 28, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2016 third quarter on Tuesday, May 3, 2016 after the market closes. Lannett management will...

More
Apr 22, 2016
--Lannett Has Exclusive U.S. Marketing Rights to Insulin Product; Fifth Project with Strategic Partner--

Lannett Company, Inc. (NYSE: LCI) today announced plans to co-develop a generic insulin pharmaceutical product for the U.S. market with its strategic partner in China, YiChang HEC ChangJiang...

More
Apr 11, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that its president, Michael J. Bogda, is leaving the company, effective June 3, 2016, to pursue other interests. "Mike spearheaded the integration...

More
Mar 29, 2016
--Company Expects to Launch Temolozomide Capsules Shortly--

Lannett Company, Inc. (NYSE: LCI) today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Potassium...

More
Mar 23, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that it has revised its fiscal 2016 full-year guidance. "We are pleased to see that shareholders have renewed confidence in our company," said...

More
Mar 14, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that its wholly owned subsidiary, Kremers Urban Pharmaceuticals Inc. (KU), and a key customer are in the process of re-establishing business...

More
Mar 14, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that, as others in its industry have recently reported, it is experiencing unanticipated market softness. As a result, the company is reviewing...

More
Mar 1, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the following investor conferences: Raymond James & Associates' 37th Annual Institutional Investors Conference on...

More
Feb 22, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Sumatriptan...

More
Feb 11, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that its wholly owned subsidiary, Kremers Urban Pharmaceuticals Inc. (KU), has received approval from the U.S. Food and Drug Administration (FDA)...

More
Feb 3, 2016
--Net Sales of $127 Million, GAAP EPS of $0.36, Adjusted EPS of $0.95; Company Reiterates Guidance for Fiscal 2016 Full Year--

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2016 second quarter and first six months ended December 31, 2015. As previously announced, the company completed...

More
Feb 1, 2016
--Initiatives Designed to Streamline Operations, Improve Efficiencies and Significantly Reduce Costs--

Lannett Company, Inc. (NYSE: LCI) today announced a number of restructuring actions (the Plan) to streamline operations, improve efficiencies and significantly reduce costs. The initiatives are...

More
Jan 26, 2016
--Net Sales of Approximately $127 Million, GAAP EPS of $0.33 to $0.36, Adjusted EPS of $0.93 to $0.95; Company to Report Full Financial Results, Host Conference Call on February 3--

Lannett Company, Inc. (NYSE: LCI) today announced that it expects to report fiscal 2016 second quarter net sales of approximately $127 million, GAAP earnings per diluted share of $0.33 to $0.36...

More
Jan 21, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that it will report preliminary fiscal 2016 second-quarter financial results, provide full-year guidance and host a related conference call on...

More
 

print email rss
Lannett Investor Relations
Lannett Company Products